FDA report positive on Bristol-Myers cancer drug

An FDA staff report says Bristol-Myers Squibb's cancer drug dasatinib appears to slow certain types of leukemia in patients who have not responded to other treatments, such as Novartis' Gleevec. An FDA advisory panel is scheduled to meet today to consider recommending approval of dasatinib for treatment of patients with three types of leukemia.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN